Identification of TAS2R-targeting bioactive compounds against metabolic decline: A novel ex vivo methodology based on enteroendocrine and inflammatory readouts

Biomedicine & Pharmacotherapy · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles